Envista Holdings Corp (NVST) P/E Ratio History
ExpensiveTrading at 96.9x vs 5Y avg 81.9x · 85th percentile · Material premium to history · Data 2019–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Envista Holdings Corp (NVST) trades at a price-to-earnings ratio of 96.9x, with a stock price of $27.13 and trailing twelve-month earnings per share of $0.41.
The current P/E is 18% above its 5-year average of 81.9x. Over the past five years, NVST's P/E has ranged from a low of 10.8x to a high of 614.3x, placing the current valuation at the 85th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, NVST trades at a 315% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
The PEG ratio of 64.89 (P/E divided by 104% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, NVST commands a significant premium over the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NVST DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NVST Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NVST P/E vs Peers
Medical Devices and Procedure Tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $13B | 32.8 | - | +1% | |
| $10B | 26.6 | 8.43 | +7% | |
| $4B | 33.9 | - | +5% | |
| $2B | 1001.4 | - | -84% | |
| $3B | 31.8 | 7.22 | -15% | |
| $120B | 37.3 | 2.51Best | +8%Best | |
| $18B | 25.2Lowest | - | -20% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NVST Historical P/E Data (2019–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | Apr 03 2026 | $25.81 | $0.41 | 63.0x | -20% |
| FY2025 Q4 | Dec 31 2025 | $21.71 | $0.28 | 77.5x | -2% |
| FY2025 Q3 | Sep 26 2025 | $20.35 | $0.09 | 234.2x | +197% |
| FY2025 Q2 | Jun 27 2025 | $19.67 | $0.31 | 62.5x | -21% |
| FY2023 Q3 | Sep 29 2023 | $27.88 | $1.08 | 25.8x | -67% |
| FY2023 Q2 | Jun 30 2023 | $33.84 | $1.24 | 27.3x | -65% |
| FY2023 Q1 | Mar 31 2023 | $40.88 | $1.20 | 34.1x | -57% |
| FY2022 Q4 | Dec 31 2022 | $33.67 | $1.34 | 25.1x | -68% |
| FY2022 Q3 | Sep 30 2022 | $32.81 | $1.15 | 28.5x | -64% |
| FY2022 Q2 | Jul 01 2022 | $39.14 | $1.32 | 29.7x | -62% |
| FY2022 Q1 | Apr 01 2022 | $48.10 | $1.51 | 31.9x | -60% |
| FY2021 Q4 | Dec 31 2021 | $45.06 | $1.47 | 30.7x | -61% |
| FY2021 Q3 | Oct 01 2021 | $42.78 | $1.77 | 24.2x | -69% |
| FY2021 Q2 | Jul 02 2021 | $43.33 | $1.46 | 29.7x | -62% |
| FY2021 Q1 | Apr 02 2021 | $40.83 | $0.68 | 60.0x | -24% |
| FY2020 Q4 | - | $33.73 | $0.22 | 153.3x | +95% |
| FY2020 Q3 | Oct 02 2020 | $24.57 | $0.04 | 614.3x | +680% |
| FY2020 Q2 | Jul 03 2020 | $21.40 | $0.38 | 56.3x | -28% |
| FY2020 Q1 | Apr 03 2020 | $12.98 | $1.20 | 10.8x | -86% |
| FY2019 Q4 | - | $29.64 | $1.61 | 18.4x | -77% |
| FY2019 Q3 | Sep 27 2019 | $26.59 | $1.66 | 16.0x | -80% |
Average P/E for displayed period: 78.7x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NVST — Frequently Asked Questions
Quick answers to the most common questions about buying NVST stock.
What is NVST's P/E ratio?
Envista Holdings Corp (NVST) trailing twelve-month P/E ratio is 96.9x, based on TTM diluted EPS of $0.41. The 5-year average P/E is 81.9x and the historical range spans 10.8x to 614.3x.
Is NVST stock overvalued or undervalued?
NVST trades at 96.9x P/E, near its 5-year average of 81.9x. The 85th percentile ranking within the 10.8x–614.3x historical range places valuation within normal bounds.
Is NVST stock expensive?
NVST is fairly valued relative to its own history. The current P/E of 96.9x is near the 5-year average of 81.9x (85th percentile of historical range).
What is NVST's historical P/E range?
Over the past 5 years, NVST's P/E ratio has ranged from 10.8x to 614.3x, with a median of 31.9x and an average of 81.9x. The current P/E of 96.9x places the stock at the 85th percentile of this range. Full historical data spans 2019–2026.
How does NVST's P/E compare to the S&P 500?
NVST trades at 96.9x P/E versus the S&P 500 median of 25.9x. The 274% premium to the market typically reflects higher expected earnings growth or quality.
How does NVST's valuation compare to Healthcare peers?
Envista Holdings Corp P/E of 96.9x compares to the Healthcare sector median of 23.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NVST's PEG ratio?
NVST PEG ratio is 64.89, based on a P/E of 96.9x and EPS growth of 104.3%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is NVST's earnings yield?
NVST earnings yield is 1.03%, the inverse of its 96.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.